ClinicalTrials.gg
Active, not recruitingNCT05149755Updated Sep 30, 2026

Evolut™ EXPAND TAVR II Pivotal Trial

An interventional study of Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT) in Moderate Aortic Valve Stenosis, sponsored by Medtronic Cardiovascular. Active, not recruiting at 94 sites in 16 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Medtronic Cardiovascular (part of Medtronic) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
650
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 116 studies in Constriction, Pathologic with a site in United States — 14 open to participants now, 18 under way, 2 of them phase 3. Constriction, Pathologic · United States.

Planned enrollment
6th of 82
650 · median 40
Started
2022
with 5 others
No phase
53 of 116
5 open now
Primary completion
2027-09
later than 10 of 17 live
Registered
93rd of 116
by date

Among the 116 studies in Constriction, Pathologic with a site in United States, this one is the 6th largest by planned enrollment of the 82 interventional ones that give a count, is one of 6 that started in 2022, is one of 53 with no phase, reaches primary completion later than 10 of the 17 other live ones, and was the 93rd registered.

Constriction, Pathologic

457 studies on the registry are indexed under Constriction, Pathologic; 110 are open to participants now.

Browse Constriction, Pathologic studies →

Open to participants now

14 of the 116 studies in Constriction, Pathologic with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 67 Constriction, Pathologic studies recruiting now, 34 (51%) set no upper age limit and 14 (21%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 116 studies in Constriction, Pathologic with a site in United States, or all of them as a file.
02

Study summary

Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.

Read the detailed description

Multi-center, international, prospective, randomized study. Subjects will be randomized to either transcatheter aortic valve replacement (TAVR) with the Evolut PRO+ TAVR System, or Evolut FX System, and guideline-directed management (GDMT) or GDMT alone.

03

Conditions studied

  • Moderate Aortic Valve Stenosis

Keywords

  • aortic
  • stenosis
  • moderate
  • valve
  • TAVR
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

o Moderate AS, defined as follows by transthoracic echo (TTE) as assessed by the ECL:

  • AVA >1.0 cm² and \<1.5cm²; or
  • AVA ≤ 1.0 cm² with AVAI > 0.6cm²/m² if \< 30 kg/m²: or
  • AVA ≤ 1.0 cm² with AVAI > 0.5cm²/m² if BMI ≥ 30 kg/m²:

and

  • Max aortic velocity ≥ 3.0 m/sec. and \< 4.0 m/sec. or
  • Mean aortic gradient ≥ 20mmHg and \< 40.0 mmHg

Any of the following at-risk features:

  • Symptoms of AS, defined as:
  • ≥ Class II, or
  • Reduced functional capacity, defined as

    • 6MWT \< 300 meters, or
    • \< 85% of age-sex predicted METs on exercise tolerance testing (ETT)
  • Documented heart failure event or hospitalization for heart failure within 1 calendar year prior to consent
  • NT-proBNP ≥ 600 pg/ml (or BNP ≥ 80 pg/ml), or
  • Persistent AF or Paroxysmal AF episode within 6 months prior to consent, or
  • Elevated aortic valve calcium score (>1200 AU for females and > 2000 AU for males) as assessed by the MDCT core lab, or
  • Any of the following by the qualifying TTE as assessed by the ECL:

    • Global longitudinal strain ≤16% (absolute value), or
    • E/e' ≥ 14.0 (average of medial and lateral velocities), or
    • Diastolic dysfunction ≥ Grade II, or
    • \< 60%
    • Stroke Volume Index \< 35 ml/m²
  • Anatomically suitable for transfemoral TAVR using the Medtronic Evolut PRO+ or Evolut FX system
  • The subject and the treating physician agree the subject will return for all required follow-up visits

Key Exclusion Criteria:

  • Age \< 65 years
  • LVEF ≤ 20% by 2-D echo
  • Class I indication for cardiac surgery
  • for placement of a bioprosthetic valve
  • Documented history of cardiac amyloidosis
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
650 participants (estimated)

Study arms

  • Experimental
    Medtronic Evolut PRO+, or Evolut FX,TAVR System, & guideline-directed management & therapy (GDMT)

    Medtronic Evolut PRO+ TAVR or Evolut FX TAVR Systems, \& guideline-directed management \& therapy

    Device: Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT)

  • No intervention
    Clinical site determined guideline-directed management and therapy (GDMT) alone

    Clinical site determined guideline-directed management and therapy (GDMT) alone

Interventions

  • DeviceMedtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT)

    Patients will have a Transcatheter Aortic Valve Replacement (TAVR) with either an Evolut PRO+ TAVR, or Evolut FX TAVR, heart valve, and given clinical site-determined guideline-directed management and therapy (GDMT).

06

What researchers measure

Primary outcomes

  1. Composite rate of all-cause mortality, all-stroke, life threatening or fatal bleeding, acute kidney injury, hospitalization due to device or procedure-related complication, or valve dysfunction requiring reintervention.

    Life threatening or fatal bleeding is defined as BARC Type 3 or 4 and acute kidney injury is defined as VARC-3 Stage IV.

    Time frame: 30 days

  2. Composite rate of all-cause mortality, heart failure hospitalization or event, or medical instability leading to aortic valve replacement or re-intervention.

    Time frame: 2 years

Secondary outcomes

  1. Proportion of subjects alive and with moderately improved quality of life (≥ 10 points in KCCQ summary score from baseline)

    Time frame: 1 year

  2. Composite of all-cause mortality and heart failure hospitalizations or events.

    Time frame: 2 years

  3. Composite of all-cause mortality, all-stroke, or unplanned CV hospitalizations

    Time frame: 2 years

  4. Heart failure hospitalizations or events.

    Time frame: 2 years

  5. All-cause mortality

    Time frame: 2 years

  6. Unplanned cardiovascular hospitalizations

    Time frame: 2 years

  7. Days alive and free of unplanned cardiovascular hospitalizations

    Time frame: 2 years

07

Study locations

94 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Sep 2027, 65 months after the start.

Of 43 industry-sponsored interventional studies with no phase under Constriction, Pathologic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 58. This study's planned 65 months is above that.

Counting every sponsor, half of 133 studies reached it within 36 months; a quarter within 18 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2021
First posted
Dec 8, 2021
StartActual
Apr 27, 2022
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2034
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05149755
Responsible party
Sponsor
First posted
Dec 8, 2021
Start date
Apr 27, 2022
Primary completion
Sep 2027 (estimated)
Completion
Dec 2034 (estimated)
Last update
Sep 30, 2026

Study contacts

Paul Sorajja, MD
principal investigator · Allina Health System
Josep Rodes-Cabau, MD
principal investigator · Fondation IUCPQ
Stephan Windecker, Prof.
principal investigator · Inselspital, Universitätsspital Bern

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion